# Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France

> **NCT06157086** · — · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 302 (actual)

## Conditions studied

- Multiple Sclerosis (MS)

## Interventions

- **OTHER:** ofatumumab

## Key facts

- **NCT ID:** NCT06157086
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-21
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06157086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06157086, "Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06157086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*